Thursday, 16 February 2012    PDF Print E-mail
'Epilepsy In Our Time'
UCB'Epilepsy In Our Time', a video diary, explores life with epilepsy from the perspective of those living with the condition on European Epilepsy Day - 13th February 2012. The disease is the most common serious brain disorder worldwide, affecting 6 million people in Europe(1). European Epilepsy Day is an initiative of the International Bureau for Epilepsy (IBE) and the International League Against Epilepsy (ILAE) and this year's theme is the burden of epilepsy.
Thursday, 01 March 2012    PDF Print E-mail
Shire receives prestigious EURORDIS Company Award for exemplary work in rare diseases
ShireShire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announced today that it has received the prestigious Company Award from the European Organisation for Rare Diseases (EURORDIS) for its exemplary work in the field of rare diseases. The EURORDIS Company Award, presented last night at the First International Rare Disease Day Gala Dinner in Brussels, is designed to reward outstanding accomplishments of pioneering companies developing treatments for rare disease.
Wednesday, 22 August 2012    PDF Print E-mail
Merck acquires cell culture media specialist Biochrom AG
Merck KGaAMerck announced today that it has entered into definitive agreements to acquire Biochrom AG located in Berlin, Germany. The company, with approximately 60 employees and sales of approximately € 13 million in 2011, specializes in the production and marketing of cell-culture media and buffer solutions. The parties agreed not to disclose the purchase price. The acquisition is subject to customary closing conditions such as the approval of the respective antitrust authority. Closing of the transaction is expected in the fourth quarter of 2012.
Wednesday, 30 May 2012    PDF Print E-mail
Jentadueto® (linagliptin/metformin hydrochloride) tablets recommended for approval
Eli Lilly and CompanyBoehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) announced they have received a positive opinion from the European Medicines Agency's (EMA) medicinal committee recommending approval of Jentadueto® (linagliptin/metformin hydrochloride) tablets, a medicine combining the DPP-4 inhibitor, linagliptin (the active ingredient in Tradjenta® tablets, marketed under the trade name Trajenta® in Europe) and metformin in a single tablet taken twice daily.
Thursday, 20 September 2012    PDF Print E-mail
Lundbeck files for regulatory approval of the novel multimodal antidepressant, vortioxetine
LundbeckH. Lundbeck A/S (Lundbeck) today announced the submission to the European Medicines Agency (EMA) of a marketing authorisation application (MAA) for the approval of the investigational multimodal antidepressant vortioxetine (Lu AA21004), and the dossier has been accepted for review. Vortioxetine belongs to a new generation of antidepressants that has been developed for the treatment of patients with major depressive episodes (MDE).

Page 7 of 292